---
layout: post
title: New Drug Approvals 2012 - Pt. XXIX - Pasireotide diaspartate (SIGNIFOR®)
date: '2013-01-06T03:16:00.000Z'
author: Ramesh
tags:
- Peptide Drugs
- 2012 New Drugs
modified_time: '2013-03-18T13:49:27.462Z'
thumbnail: http://2.bp.blogspot.com/-xWsa4aMU-GQ/UObsnB4cQTI/AAAAAAAAAEY/jhdj2bneP7o/s72-c/seqAligment.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-854806102530972415
blogger_orig_url: http://chembl.blogspot.com/2013/01/new-drug-approvals-2012-pt-xxix.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.globalpharmasectornews.com/wp-content/uploads/2012/12/Signifor.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="302" src="http://www.globalpharmasectornews.com/wp-content/uploads/2012/12/Signifor.jpg" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,0,0,0" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="46" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,0,0,0" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<b>ATC code:</b> H01CB05</div>
<div class="separator" style="clear: both; text-align: center;">
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Pasireotide">Pasreotide</a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
On December 14, the FDA approved&nbsp;Pasireotide diaspartate (SIGNIFOR®, Research CodeL SOM-230, CAS#&nbsp;<a href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=396091-73-9&amp;rn=1">396091-73-9</a>, Pub-Chem :&nbsp;<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9941444">CID 9941444</a>, KEGG :&nbsp;<a href="http://www.kegg.jp/entry/D10147">D10147</a>), a cyclohexide with pharmacologic properties mimicking those of natural hormone <a href="http://en.wikipedia.org/wiki/Somatostatin" target="_blank">Somatostatin</a> for treatment of adult patients with <a href="http://en.wikipedia.org/wiki/Cushing%27s_disease" target="_blank">Cushing's disease</a>&nbsp;(CD) for whom pituitary surgery is not an option or has not been curative.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
Cushing's disease (CD) is a cause of <a href="http://en.wikipedia.org/wiki/Cushing%27s_syndrome" target="_blank">Cushing's syndrome</a> characterised by increased secretion of ACTH (adrenocorticotropic hormone) from the anterior pituitary. CD is a rare hormone disorder, and &nbsp;recent statistics indicate that the annual incidence is somewhere between 1 and 10 per million and is 3 times more common in women than in men (from <a href="http://endocrine.niddk.nih.gov/pubs/cushings/cushings.aspx" target="_blank">NEMDIS</a>). This is most often as a result of pituitary <a href="http://en.wikipedia.org/wiki/Adenoma" target="_blank">adenoma</a>&nbsp;or due to excess production of hypothalamus Corticotropin releasing hormone (<a href="http://en.wikipedia.org/wiki/Corticotropin_releasing_hormone" target="_blank">CRH</a>). More information can be found in <a href="http://emedicine.medscape.com/article/117365-overview#a0101" target="_blank">Medscape</a>.</div>
<div class="separator" style="clear: both; text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.aafp.org/afp/2000/0901/afp20000901p1119-f2.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="http://www.aafp.org/afp/2000/0901/afp20000901p1119-f2.gif" width="285" /></a></div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
The therapeutic activity of Pasireotide diaspartate is through binding to Somatostatin receptors (<a href="http://en.wikipedia.org/wiki/Somatostatin_receptor" target="_blank">SSTRs</a>). They belong to <a href="http://en.wikipedia.org/wiki/G_protein-coupled" target="_blank">GPCR</a> class of targets and there are five known SSTRs in human: <b><i>SSTR1</i></b> (<a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1917" target="_blank">CHEMBL1917</a>;&nbsp;<a href="http://www.uniprot.org/uniprot/P30872">P30872</a>), <b><i>SSTR2</i></b> (<a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1804" target="_blank">CHEMBL1804</a>;&nbsp;<a href="http://www.uniprot.org/uniprot/P30874">P30874</a>), <b><i>SSTR3</i></b> (<a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL2028" target="_blank">CHEMBL2028</a>;&nbsp;<a href="http://www.uniprot.org/uniprot/P32745">P32745</a>), <b><i>SSTR4</i></b> (<a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1853" target="_blank">CHEMBL1853</a>;&nbsp;<a href="http://www.uniprot.org/uniprot/P31391">P31391</a>) and <b><i>SSTR5</i></b> (<a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1792" target="_blank">CHEMBL1792</a>;&nbsp;<a href="http://www.uniprot.org/uniprot/P35346">P35346</a>). These receptor subtypes are expressed in different tissues under normal physiological condition. Corticotroph tumor cells from CD patients frequently over express SSTR5, whereas the other receptor subtypes are often not expressed or expressed at lower levels.&nbsp;Pasireotide diaspartate has a 40-fold increased affinity to SSTR5 than other SSTR analogs binds and activates the receptors resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-xWsa4aMU-GQ/UObsnB4cQTI/AAAAAAAAAEY/jhdj2bneP7o/s1600/seqAligment.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="640" src="http://2.bp.blogspot.com/-xWsa4aMU-GQ/UObsnB4cQTI/AAAAAAAAAEY/jhdj2bneP7o/s640/seqAligment.png" width="404" /></a></div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
Since the targets of this drug belong to same family of receptors (somatostatin receptors), multiple &nbsp;sequence alignment of human SSTR1, 2, 3, 4 and 5 receptors was done using <a href="http://tcoffee.crg.cat/apps/tcoffee/do:regular">T-coffee</a> which is shown above. The protein sequences&nbsp;(fasta format)&nbsp;of human SSTR1, 2, 3, 4 and 5 can be downloaded from this <a href="http://www.uniprot.org/uniprot/?query=P32745+OR+P30874+OR+P35346+OR+P31391+OR+P30872&amp;format=fasta">link</a> here. (<i>courtesy UniProt</i>)</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-I_2hA12-8FI/UObZXRbBmII/AAAAAAAAAEI/YxpFclF5XuE/s1600/Screen+Shot+2013-01-04+at+13.29.38.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="218" src="http://2.bp.blogspot.com/-I_2hA12-8FI/UObZXRbBmII/AAAAAAAAAEI/YxpFclF5XuE/s400/Screen+Shot+2013-01-04+at+13.29.38.png" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
</div>
<div class="separator" style="clear: both; text-align: left;">
Standard InChI : 1/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1/f/h61,63-67H</div>
<div class="separator" style="clear: both;">
<br /></div>
<div>
Smiles : NCCCC[C@H]1C(N[C@H](C(N[C@H](C(N2[C@H](C(N[C@H](C(N[C@@H](C(N1)=O)CC1=CNC3=CC=CC=C13)=O)C1=CC=CC=C1)=O)C[C@H](C2)OC(NCCN)=O)=O)CC2=CC=CC=C2)=O)CC2=CC=C(C=C2)OCC2=CC=CC=C2)=O</div>
<div>
</div>
<div style="text-align: left;">
Iupac Name :&nbsp;<span style="text-align: justify;">(2-Aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxybenzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosuccinic acid] salt</span></div>
<div>
<span style="text-align: justify;"><br /></span></div>
<br />
<div class="separator" style="clear: both; text-align: justify;">
Pasireotide diaspartate&nbsp;is a Somatostatin analog and is cyclohexapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. The recommended dosage range of&nbsp;Pasireotide diaspartate is 0.3 to 0.9 mg administered as subcutaneous injection twice a day.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
Pasireotide diaspartate demonstrates approximately linear pharmacokinetics for a dose range from 0.0025 to 1.5 mg in healthy patients with dose proportional Cmax and AUC and Tmax of 0.25 to 0.5 hrs. Apparent volume of distribution (Vz/F) was &gt;100 L with plasma concentration of about 91%. Plasma protein binding was moderate (88%). It is shown to be metabolically stable in human liver and kidney and is eliminated mainly via hepatic clearance.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Full prescribing information can be found <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo">here</a>.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
The license holder is <a href="http://www.novartis.com/">Novartis Pharmaceuticals</a>, and the product website is <a href="http://www.signifor.com/">www.signifor.com</a>.</div>
</div>
